German biotech companies at the forefront in the development of nucleic acid-based drugs in the “Leap Innovations” category MUNICH–(BUSINESS WIRE)–On 13 September, the winners of the “Most Innovative Product” award in the category “Leap Innovations” were announced at the “Pharma Trend – Image & Innovation Award”. Cardior Pharmaceuticals came out on top, ahead of RNATICS, … [Read more…]
DALLAS–(BUSINESS WIRE)–$LTRN—Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“A.I.”) and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will present preclinical data on the potency of Lantern’s drug candidate LP-284 for mantle cell … [Read more…]
ST. LOUIS & SAN DIEGO–(BUSINESS WIRE)–Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced that management will participate in a fireside chat at 1:30 p.m. ET on Friday, September 30, 2022 at the upcoming Jefferies Cell & Genetic … [Read more…]
DecisionDx-Melanoma integrates a patient’s clinicopathologic factors with his/her tumor biology to provide precise, personalized risk estimates, including five-year melanoma-specific survival, recurrence-free survival and distant metastasis-free survival FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL #CSTL–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal … [Read more…]
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Sonendo, Inc. (NYSE: SONX), a leading dental technology company and developer of the GentleWave® System, today announced a private placement of common stock and pre-funded warrants, resulting in gross proceeds of $63 million. New and existing investors, including Pura Vida Investments, First Light Asset Management, Blue Water Life Science Advisors, ArrowMark Partners, … [Read more…]
— Multiple tranche debt financing provides Spectrum with up to $65 million — — Funding provides additional capital to optimize commercial launch of ROLVEDON™ — — Cash runway extended through 2024 — BOSTON–(BUSINESS WIRE)–Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that … [Read more…]
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces that management will present at the Ladenburg Thalmann 2022 Healthcare Conference on Thursday, September 29 at 9:00 a.m. Eastern time (6:00 a.m. Pacific time). The conference is being held at the Sofitel … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Global Neurotrophic Keratitis Market (2022-2027) by Route of Administration, Distribution Channel, and Geography, with Competitive Analysis, Impact of COVID-19, and Ansoff Analysis” report has been added to ResearchAndMarkets.com’s offering. The Global Neurotrophic Keratitis Market is estimated to be worth USD 191.1 million in 2022, and is expected to reach USD 439.05 million by … [Read more…]
SAN DIEGO–(BUSINESS WIRE)–$JANX—Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Brenda Van Vreeswyk as Head of Human Resources (HR). Ms. Van Vreeswyk brings … [Read more…]
SAN DIEGO–(BUSINESS WIRE)–AlivaMab Discovery Services (“ADS”), a leader in the discovery of superior antibody-based therapeutics, announced that Larry Green has reassumed the role of Chief Executive Officer, effective immediately. He assumes the role from Justin Mika. Dr. Green, who brings over 30 years’ experience in antibody drug discovery and development, is the founding Chief Executive … [Read more…]
